



SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

under Rule 62a and/or 63 of the European Patent Convention. This report shall be considered, for the purposes of subsequent proceedings, as the European search report

Application number:
EP 16 78 71 10

Classification of the application (IPC):
A61K 39/00, A61K 39/39, A61K 31/36, A61K 31/381, A61K 31/16

Technical fields searched (IPC):
A61K, C07K

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
Y	M. A. SCHWARTZ ET AL: "Integrin Agonists as Adjuvants in Chemotherapy for Melanoma" <i>CLINICAL CANCER RESEARCH</i> US 01 October 2008 (2008-10-01), vol. 14, no. 19, DOI: 10.1158/1078-0432.CCR-08-1285, ISSN: 1078-0432, pages 6193-6197, XP055531739 * page 6196 - page 6197; figures 3, 4 *	1, 8-13
T	ALESSANDRA TOLOMELLI ET AL: "Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators" <i>CANCERS</i> , 05 July 2017 (2017-07-05), vol. 9, no. 12, DOI: 10.3390/cancers9070078, page 78, XP055531258	
Y	SIMON L GOODMAN ET AL: "Integrins as therapeutic targets" <i>TRENDS IN PHARMACOLOGICAL SCIENCES</i> , 01 July 2012 (2012-07-01), vol. 33, no. 7, DOI: 10.1016/J.TIPS.2012.04.002, ISSN: 0165-6147, pages 405-412, XP028495741 * page 408 - page 410 *	1, 8-13
Y	ANDREW M. SCOTT ET AL: "Antibody therapy of cancer" <i>NATURE REVIEWS. CANCER</i> GB 01 April 2012 (2012-04-01), vol. 12, no. 4, DOI: 10.1038/nrc3236, ISSN: 1474-175X, pages 278-287, XP055531673 * the whole document *	1, 8-13
Y	WO 2012068251 A2 (TEXAS HEART INST [US]; BIEDIGER RONALD J [US]; GUNDLACH IV C WILLIAM J) 24 May 2012 (2012-05-24) * page 47 lines 7/8, page 57 formula 2-18, page 79 second-last line - page 80 first line *	1, 8-13
INCOMPLETE SEARCH		
The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC so that only a partial search (R. 62a, 63) has been carried out.		

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search Munich	Date of completion of the search 10 December 2018	Examiner Heder, Andreas
---------------------------	--	----------------------------

CATEGORY OF CITED DOCUMENTS

- | | |
|---|--|
| X: particularly relevant if taken alone | P: intermediate document |
| Y: particularly relevant if combined with another document of the same category | T: theory or principle underlying the invention |
| A: technological background | E: earlier patent document, but published on, or after the filing date |
| O: non-written disclosure | D: document cited in the application |
| | L: document cited for other reasons |
| & : member of the same patent family, corresponding document | |

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

under Rule 62a and/or 63 of the European Patent Convention. This report shall be considered, for the purposes of subsequent proceedings, as the European search report

Application number:
EP 16 78 71 10

INCOMPLETE SEARCH

Claim(s) completely searchable: 2-7, 11-13

Claim(s) searched incompletely: 1, 8-10

Claim(s) not searched:

Reason for the limitation of the search:

[0001] Claims 1-9 relate to compositions and medical uses involving a very large number of "activating compounds" which vaguely are defined as "activating integrin mediated interactions with their cognate ligands". The Markush formulae defining said compounds relate to a very high number of possible compounds, while there is no support in the application regarding the activity as integrin agonists for most of said compounds. Furthermore, the claims are unduly broad, and speculative. Of note, the experimental data section (pp. 43-50 of the application) discloses only the use of one compound, C4, in anti-CTLA-4 antibody therapy of a cancer model disease.

[0002] Claims 1-10 can only be searched insofar as they relate to the compounds recited in claims 11-13. Furthermore, claims 11 and 12 recite numerous compounds which appear to be speculative with regard to their alleged function as integrin agonists. The only compounds for which such function may potentially be regarded as being supported are those referred to in claim 13 (see also Table I, page 44).

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search Munich	Date of completion of the search 10 December 2018	Examiner Heder, Andreas
---------------------------	--	----------------------------

CATEGORY OF CITED DOCUMENTS

- | | |
|---|--|
| X: particularly relevant if taken alone | P: intermediate document |
| Y: particularly relevant if combined with another document of the same category | T: theory or principle underlying the invention |
| A: technological background | E: earlier patent document, but published on, or after the filing date |
| O: non-written disclosure | D: document cited in the application |
| | L: document cited for other reasons |
| & : member of the same patent family, corresponding document | |

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

under Rule 62a and/or 63 of the European Patent Convention. This report shall be considered, for the purposes of subsequent proceedings, as the European search report

Application number:
EP 16 78 71 10

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1, 8-10

Compositions comprising integrin agonist, and an antibody, medical use thereof

2. claims: 2-6

Vaccine preparation comprising integrin agonist, and an antigen

3. claim: 7

Pharmaceutical preparation comprising integrin agonist, and NK cells

None of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the first mentioned in the claims, namely claims: 1, 8-10(completely); 11-13(partially)

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search Munich	Date of completion of the search 10 December 2018	Examiner Heder, Andreas
---------------------------	--	----------------------------

CATEGORY OF CITED DOCUMENTS

- | | |
|---|--|
| X: particularly relevant if taken alone | P: intermediate document |
| Y: particularly relevant if combined with another document of the same category | T: theory or principle underlying the invention |
| A: technological background | E: earlier patent document, but published on, or after the filing date |
| O: non-written disclosure | D: document cited in the application |
| &: member of the same patent family, corresponding document | L: document cited for other reasons |

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.



ANNEX TO SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

Application number:
EP 16 78 71 10

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 10-12-2018
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012068251 A2	24-05-2012	AU 2011328904 A1	06-06-2013
		AU 2017201804 A1	06-04-2017
		AU 2018236756 A1	18-10-2018
		AU 2018236763 A1	18-10-2018
		CA 2818336 A1	24-05-2012
		CA 2997471 A1	24-05-2012
		CA 2997474 A1	24-05-2012
		DK 2640721 T3	02-07-2018
		DK 2881392 T3	23-07-2018
		DK 2881393 T3	23-07-2018
		EP 2640721 A2	25-09-2013
		EP 2881392 A1	10-06-2015
		EP 2881393 A1	10-06-2015
		EP 3388429 A1	17-10-2018
		ES 2675914 T3	13-07-2018
		ES 2677668 T3	06-08-2018
		ES 2677669 T3	06-08-2018
		HK 1211291 A1	20-05-2016
		HK 1211292 A1	20-05-2016
		IL 226382 A	28-02-2018
		IL 257517 A	31-12-2018
		IL 257518 A	31-12-2018
		US 2013236434 A1	12-09-2013
		US 2015291571 A1	15-10-2015
		US 2015368234 A1	24-12-2015
		US 2017044130 A1	16-02-2017
		WO 2012068251 A2	24-05-2012